Toripalimab-Based Cisplatin-Free Strategy Efficacious, safe in Advanced NPC: JAMA
Researchers have found in a phase 3 trial that toripalimab combination therapy without cisplatin proved feasible, offering high failure-free survival and low toxicity in locoregionally advanced nasopharyngeal carcinoma (NPC). This study was published in JAMA by The DIAMOND Study Group. NPC is a cancerous tumor that originates from the nasopharynx and has a high incidence […]